Impact of applying machine learning to the electronic medical record on prediction of cancer-associated thrombosis. Breakdown for provider order entry and pharmacist review with and without drug ...
The ideas and opinions expressed in these Data Supplements do not necessarily reflect those of the American Society of Clinical Oncology (ASCO). The mention of any product, service, or therapy in ...
Health care disparities and bladder cancer mortality in the United States: A closer look at the social vulnerability index. This is an ASCO Meeting Abstract from the 2024 ASCO Quality Care Symposium.
“Tell me I’m okay”: A cross-sectional quality-of-life assessment of patients in a breast cancer survivorship program. This is an ASCO Meeting Abstract from the 2024 ASCO Quality Care Symposium. This ...
Understanding health literacy's moderating role in remote monitoring for adjuvant endocrine therapy: Findings from a randomized clinical trial. Associations of Medicaid expansion with stage at ...
Quality improvement scorecards driving innovation and best practice in a large community oncology practice.
Influence of an AYA cancer program on cancer care delivery.
The impact of oral oncology drugs in the era of value-based care. Median spending in 6 months after cancer diagnosis (in 2021 dollars), adjusted for age and sex.
Healthcare spending and out-of-pocket burden for working-aged adults after a cancer diagnosis.
Improving distress screening in radiation oncology consultation. This is an ASCO Meeting Abstract from the 2024 ASCO Quality Care Symposium. This abstract does not include a full text component.
Financial realities of fighting cancer: A close look at patient responsibility with part D coverage.
The cost of doing business: Drug costs in federally sponsored cancer clinical trials.
Outcomes with initiation of inpatient immunotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback